Diagnosis of Cystic Echinococcosis, Central Peruvian Highlands by Gavidia, Cesar M. et al.
We evaluated prevalence of cystic echinococcosis (CE) 
in a central Peruvian Highland district by using 4 diagnostic 
methods: ultrasonography for 949 persons, radiography for 
829, and 2 serologic tests for 929 (2 immunoblot formats us-
ing bovine hydatid cyst ﬂ  uid [IBCF] and recombinant EpC1 
glutathione S-transferase [rEpC1-GST] antigens). For the 
IBCF and rEpC1-GST testing, prevalence of liver and pul-
monary CE was 4.7% and 1.1% and seropositivity was 8.9% 
and 19.7%, respectively. Frequency of seropositive results 
for IBCF and rEpC1-GST testing was 35.7% and 16.7% (all 
hepatic cysts), 47.1% and 29.4% (hepatic calciﬁ  cations ex-
cluded), and 22.2% and 33.3% (lung cysts), respectively. 
Weak immune response against lung cysts, calciﬁ  ed cysts, 
small cysts, and cysts in sites other than lung and liver 
might explain the poor performance of the serodiagnostic 
tests. We conﬁ  rm that CE is highly endemic to Peru and 
emphasize the limited performance of available serologic 
assays in the ﬁ  eld.
C
ystic echinococcosis (CE), caused by the larval stage 
of Echinococcus granulosus, is recognized as a pub-
lic health problem (1). Cysts develop in internal organs of 
intermediate hosts (herbivores and humans). The disease 
represents a challenge of increasing concern in countries 
where control programs have been reduced or have not yet 
been implemented (2,3). Globally, the annual loss due to 
human hydatidosis (treatment and lost income) has been 
estimated at ≈US $200 million (4).
CE is endemic to >100 countries in Latin America, 
Asia, and Africa (1,5) and is considered an emerging dis-
ease in other areas. In the former Soviet Union and Eastern 
Europe, the number of cases has dramatically increased in 
recent years (6–8). The annual incidence of CE hospital 
cases has reached >8/100,000 persons in some European 
countries, and 42/100,000 in Xinjiang, People’s Repub-
lic of China (5). The highest incidence of surgical cases 
(198/100,000) has been reported in Kenya (1). A few areas 
(Iceland, Ireland, and Greenland) are believed to be free of 
autochthonous transmission. The United States has report-
ed a few cases in livestock; most CE infections in persons 
are imported. This is also true for regions of western and 
central Europe (4) with the exception of countries such as 
Spain, where the parasite is prevalent and remains a major 
public health problem (9,10).
Studies in Peru have shown high prevalence of CE in 
humans, particularly in the central and southern highlands 
(11,12). During 1997–1999, prevalence in the central An-
des was 5.7%–9.3% according to ultrasonography, radiog-
raphy, or both and up to 18.2% according to immunoblot 
testing (11,12). Portable ultrasonography has facilitated the 
study and more accurate reporting of CE prevalence in en-
demic regions (13,14), following the standardized World 
Health Organization classiﬁ  cation (15).
Among available serologic tests, the immunoblot (IB) 
assay that uses bovine hydatid cyst ﬂ  uid (IBCF) has been 
successfully used in CE-endemic areas of Peru (12,14). 
This IBCF has a sensitivity of 80% for hepatic cysts and 
56% for pulmonary cysts (16). Another immunoblot test, 
which uses a puriﬁ  ed recombinant EpC1 glutathione S-
transferase antigen (rEpC1-GST), has a sensitivity of 92.2% 
and a speciﬁ  city of 95.6% (17). An immunoreactive clone 
(EpC1), encoding EpC1 was identiﬁ  ed by immunoscreen-
ing a cDNA library constructed with RNA extracted from 
protoscolices from sheep hydatid cysts. Immunoglobulin 
(Ig) G was the dominant antibody isotype generated against 
rEpC1-GST (17). To this point, no ﬁ  eld testing of the EpC1 
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had been undertaken. Measuring the real extent of CE in 
South America as well as evaluating the native, recombi-
nant, and peptide antigens for diagnosis of CE in humans 
have been recommended (18). During July and August 
2004, we used 4 diagnostic methods—ultrasonography, 
chest radiography, and 2 serologic assays—to evaluate the 
prevalence of CE in humans in an unexplored CE-endemic 
area of the central Peruvian Highlands where control mea-
sures have been attempted incompletely.
Materials and Methods
Study Site
We selected 9 rural communities located 5–50 km 
from Yanahuanca district, which is located in the Pasco de-
partment (central Peruvian Andes) at 3,249–4,314 m above 
sea level (Figure 1). The terrain is mountainous and roads 
are unpaved. Houses are made of adobe, and drinking wa-
ter is obtained from streams or rivers. Primary healthcare 
is provided by health centers; specialized care is available 
from the closest hospital in Pasco (40–60 km).
Sheep (n = 99,175) are the dominant livestock, but 
cattle (n = 5,451), swine (n = 2,784), alpacas (n = 2104), 
llamas (n = 5,679), and guinea pigs (n = 8,870) (19) are 
raised for human consumption. With the exception of 
guinea pigs, animals are kept in ﬁ  elds distant from the 
villages. Dogs are routinely used as shepherds, but some 
are kept as pets.
Study Design
After coordination with local authorities, a census was 
taken of persons in each village; to maintain conﬁ  dentiality, 
persons were assigned a code. A cross-sectional study was 
performed by using ultrasonography of the abdomen, radi-
ography of the chest, and 2 immunoblot assays with differ-
ent antigens (crude IBCF [16] and a recombinant antigen 
rEpC1-GST [17]). Persons >5 years of age were invited to 
participate. All examinations were conducted at communi-
ty health centers; 3–4 mL of blood was taken from all per-
sons who volunteered to participate in the study. Women 
of childbearing age were asked to have a urine pregnancy 
test, and those who were pregnant were excluded from ra-
diographic examination. The ethics review boards of the 
Universidad Peruana Cayetano Heredia and the Bloomberg 
School of Public Health of Johns Hopkins University ap-
proved the study and written consent forms.
Radiography
Posterior-anterior portable radiographs were taken by 
using a Polyskop machine (Siemens, Orlando, FL, USA). 
A radiologist, who was not provided serologic and ultraso-
nography results, read the ﬁ  lms and classiﬁ  ed the ﬁ  ndings 
by using the Beggs criteria for lung CE (20). Unruptured 
cysts were deﬁ  ned as centrally located, closed, well-de-
ﬁ  ned, and round lesions.
Ultrasonography
Ultrasonography was performed with a portable 3.5-
MHz ultrasonograph (model Shimasonic SLD-32, Shimat-
zu, Kyoto, Japan). Cysts were diagnosed by using the inter-
national classiﬁ  cation of ultrasound images for CE, which 
classiﬁ  es cysts in cystic lesions, and from CE type 1 to CE 
type 5 according to their development grade or degenera-
tion (15).
IBCF Immunoblot
Bovine hydatid cysts were obtained from abattoirs, 
and ﬂ  uid was aspirated and placed in a beaker at 4°C to 
which 0.5 M phenylmethylsulfonyl ﬂ  uoride (Sigma, St. 
Louis, MO, USA) was added (1:100 dilution). After cen-
trifugation at 3,000 g for 10 min, the supernatant was ly-
ophilized and stored at –20°C until use. The antigen was 
diluted with 0.1% sodium dodecyl sulfate (SDS), 0.025 
(w/v) bromophenol blue, 0.0025 M Tris-HCl (pH 8.0), and 
the dilution was completed with 6% glycerol to give a ﬁ  nal 
concentration of 0.2 μg/μL. The antigen was resolved by 
polyacrylamide gel electrophoresis as described elsewhere 
(16,21). The separated proteins were electrotransferred to 
nitrocellulose membrane, cut into strips, and immersed in 
a dilution of 1:25 (serum:phosphate-buffered saline with 
0.3% Tween 20). Bound human antibodies were detected 
by incubating each strip in horseradish peroxidase–conju-
gated goat antibody to human IgG at a dilution of 1:1,000. 
Antibodies bound to diagnostic bands of 8, 16, and 21 kDa 
were seen after addition of 3,3′-diaminobenzidine. A posi-
tive result was deﬁ  ned as the presence of any diagnostic 
band (16).
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 2, February 2008  261 
Figure 1. Map of the Central Peruvian Highlands.RESEARCH
rEpC1-GST Immunoblot
rEpC1-GST was expressed in Escherichia coli (21). 
The rEpC1-GST fusion protein was subjected to electro-
phoresis on 12% (w/v) SDS-polyacrylamide gels under re-
ducing conditions and then transferred onto nitrocellulose 
membrane; the membrane was then cut into strips contain-
ing ≈0.3 μg of rEpC1-GST protein, as described (17). Af-
ter being blotted with 5% (w/v) skim milk, the strips were 
incubated with human serum samples (diluted 1:100) for 1 
h at 37°C and washed 3× with phosphate-buffered saline 
Tween before being incubated with goat anti-human whole 
immunoglobulin IgG conjugate (Sigma). After develop-
ment in 4-chloro-1-naphanol substrate solution for 15 min 
at room temperature, the strips were examined. A positive 
serum sample showed a band of ≈41 kDa (17).
Data Analysis
The prevalence of CE was determined for the 2 imag-
ing techniques, and the proportion of seropositive persons 
was estimated according to serologic test results. The test 
prevalence was calculated for all communities, and the dif-
ference was assessed by a 2-sample test of proportions. The 
χ2 test was used to evaluate the association of sex with posi-
tive results for all 4 tests. The frequency of seropositivity 
(by IBCF or rEpC1-GST) for persons who had CE-positive 
ultrasonographic or radiographic images was calculated to 
evaluate the performance of the immunoblot tests. This fre-
quency was, moreover, assessed with and without hepatic 
calciﬁ  ed cysts, and for liver cysts <20 mm (24 persons) or 
>20 mm (18 persons) in diameter. The κ test was used to 
establish the agreement between the 2 serologic assays and 
with either ultrasonography or radiography. All statistical 
analyses were computed by using Stata 8.0 (Stata Corpora-
tion, College Station, TX, USA) with a signiﬁ  cance level 
of <0.05.
Results
Of the 1,973 persons registered during the census, 
137 (7%) were <5 years of age, which left 1,836 poten-
tial study participants. Of these, 949 persons (51.7%) were 
examined. All 949 were evaluated with ultrasonography, 
829 had chest radiographs taken, and 929 contributed blood 
samples. The proportion of females was higher among par-
ticipants (60.3%) than nonparticipants (50%) (p<0.05). Of 
those with ultrasonographic results, 39 had no serologic 
results because they refused to have their blood collected. 
In addition, 125 persons had serologic results but refused 
to have chest radiographs taken. The ages of participants 
and community members were similar (mean age 28.8 and 
28 years, respectively) when children <5 years of age were 
excluded from analysis.
Ultrasonography showed prevalence of CE in the liver 
to be 4.7% (45/949); radiography showed prevalence of CE 
in the chest to be 1.1% (9/829). Two persons had cysts in the 
liver and lungs. Therefore, the CE prevalence according to 
ultrasonography and radiography was 5.5% (52/949; 95% 
conﬁ  dence interval [CI] 4.1%–7.1%). Seropositivity ac-
cording to IBCF was 8.9% (83/929; 95% CI 7.2%–10.9%); 
seropositivity according to rEpC1-GST was signiﬁ  cantly 
higher at 19.7% (184/929; 95% CI 17.2%–22.4%, p<0.01). 
All 83 IBCF-positive persons reacted to the 16-kDa band; 
the bands of 21 and 8 kDa were observed for 78 and 76 per-
sons, respectively. No differences were found among the 
9 communities (Table 1). When participants were divided 
into 2 groups according to median age (<23 and >23 years), 
no difference was found for proportion of those who were 
positive by serologic assay and by radiographic examina-
tion; however, a signiﬁ  cant difference existed according 
to ultrasonographic examination (14/456 [3.1%] for those 
<23 years vs. 31/493 [6.3%] for those >23 years; p<0.05).
The total number of liver cysts was 50 (5 persons had 
2 liver cysts each); the total number of lung cysts was 10 in 
9 persons. The lung-to-liver ratio was 1:5. Most of the liver 
cysts were classiﬁ  ed as CE5 (54%, 27/50), inactive cysts 
with calciﬁ  ed walls, followed by CE1 (20%, 10/50) active 
cysts and CE2 (10%, 5/50). Types CE3 and CE4 with signs 
of initial degeneration (8% each, 4/50) were rare (Figure 2). 
The average age was similar for persons with CE1, CE4, 
and CE5 at 40.6, 40.9, and 40 years of age, respectively. 
Those with CE2 and CE3 averaged 28.8 and 23.3 years of 
age, respectively.
The frequency of persons in the group that had CE-posi-
tive imaging results who also had IBCF-positive results was 
47.1% (8/17; 95% CI 23%–72.2%) for hepatic noncalciﬁ  ed 
cysts, 35.7% (15/42; 95% CI 21.6%–52%) when hepatic cal-
ciﬁ  ed cysts were included, and 22.2% (2/9; 95% CI 2.8%–
60%) for pulmonary cysts. Of the 52 persons who had CE 
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Table 1. Immunoblot assay results for cystic echinococcosis, 
central Peruvian Highlands, using 2 immunoblot assays with 
different antigens* 
Antigen, no. (%) positive 
Community 
No.
samples IBCF rEpC1-GST 
Tambochaca 62 2 (3.2)  17 (27.4) 
Huarautambo  54 2 (3.7)  10 (18.5) 
Astobamba 79 5 (6.3)  12 (15.2) 
Santiago Pampa  213 17 (8)  35 (16.4) 
12 de Octubre  84 11 (13.1)  10 (11.9) 
Andachaca 118 11 (9.3)  25 (21.2) 
Uchumarca 113 15 (13.3)  27 (23.9) 
Tambopampa  107 10 (9.4)  30 (28) 
Ayayog  74 6 (8.1)  14 (18.9) 
Other†  25 4 (16)  3 (12) 
Total 929 83 (8.9)‡  183 (19.7)‡ 
*IBCF, antigen was bovine hydatid cyst fluid; rEpC1-GST, antigen was 
recombinant EpC1 glutathione S-transferase. 
†Group of volunteers who came from nearby communities and were also 
included in the survey. 
‡Statistically different (p<0.01), with higher percentage of seropositivity for 
rEpC1-GST than IBCF. Cystic Echinococcosis, Central Peruvian Highlands
in liver, lungs, or both, 49 provided serum samples (3 who 
had positive ultrasonography results did not provide a blood 
sample). The frequency of persons in the group that had CE-
positive imaging results who also had rEpC1-GST–positive 
results was 16.7% (7/42; 95% CI 7%–31.3%) for all hepatic 
cysts, and 29.4% (5/17; 95% CI 10.3%–56%) when hepatic 
calciﬁ  ed cysts were excluded. This test detected 33.3% (3/9; 
95% CI 7.5%–70%) of those with CE-positive chest radio-
graphs. Neither serologic test detected >50% of persons with 
presumptive CE imaging results (Table 2). However, the 
IBCF was >2× as sensitive as the rEpC1 for detecting per-
sons with CE-positive imaging results.
Of the 2 persons who had cysts in lung and liver, 1 
had positive results for both serologic tests and the other 
had negative results for both. The frequency of seropositiv-
ity for persons with liver cysts <20 mm in diameter was 
25% (6/24) for IBCF and 4% (1/24) for rEpC1-GST. In 
contrast, the frequency for persons with liver cysts >20 
mm in diameter was 50% (9/18) for IBCF and 33% (6/18) 
for rEpC1-GST. A signiﬁ  cant difference in detecting cysts 
with diameters <20 mm versus >20 mm was found for only 
rEpC1-GST (4%– 33%, p<0.05).
The agreement between IBCF and rEpC1-GST was 
only 8%, which would be expected by chance alone (κ = 
0.08, p<0.01). Of 928 participants, 26 were positive by 
both serologic tests (2.8%), and 688 (74.1%) were negative 
by both. A total of 157 persons who had IBCF-negative re-
sults had rEpC1-GST–positive results; 57 who had IBCF-
positive results had rEpC1-GST–negative results. CE-test 
positivity was not signiﬁ  cantly associated with sex accord-
ing to any diagnostic test (Table 3).
To assess possible cross-reactions with cysticercosis, 
we evaluated serum by using a puriﬁ  ed glycoprotein Tae-
nia solium antigen, in an immunoblot format (18). At the 
population level, antibodies to T. solium cysticercosis did 
not affect hydatid serologic assay results. The seropreva-
lence of cysticercosis was statistically similar for hydatid-
seropositive and hydatid-seronegative persons, regardless 
of the antigen used to diagnose hydatidosis (IBCF: 11/83, 
13.3% vs. 103/852, 12.1%, respectively; rEpC1-GST: 
24/184, 13% vs. 90/750, 12%, respectively). Similarly, at 
the population level, the seroprevalence of E. granulosus 
antibodies was similar for cysticercosis-seropositive and 
cysticercosis-seronegative persons, regardless of the anti-
gen used to detect Echinococcus (IBCF: 11/114, 9.7% vs. 
72/821, 8.8%, respectively; rEpC1-GST: 24/114, 21.1% 
vs. 160/820, 19.5%, respectively).
Discussion
This study demonstrates and conﬁ  rms the high preva-
lence of CE in humans in the central Peruvian Highlands. 
It also highlights the limited performance of 2 immunob-
lot tests (IBCF and rEpC1-GST) under ﬁ  eld conditions 
by detecting <50% of persons who had CE-positive im-
aging results. We show the utility of ultrasonography for 
CE screening, which demonstrated an elevated percentage 
(54%) of apparently inactive and calciﬁ  ed hepatic cysts.
The survey was well accepted by the study popula-
tion. However, most of the participants were women; men 
tend to be more reluctant to participate in medical studies, 
especially those involving blood sampling. The CE preva-
lence of 5.5% found by ultrasonography and radiography is 
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Figure 2. Ultrasonographic images of cystic echinococcosis in the liver in patients from the Yanahuanca district, Central Peruvian Highlands. 
A) Cyst type CE1; B) Cyst type CE2; C) Cyst type CE4. 
Table 2. Frequency of seropositive results among persons with cystic echinococcosis–positive ultrasonography and radiography 
imaging results, central Peruvian Highlands* 
Ultrasonography,† % (95% CI)  Overall,§ % (95% CI) 
Antigen With calcification  Without calcification  Radiography‡  With calcification  Without calcification 
IBCF 35.7 (21.6–52)  47.1 (23–72.2)  22.2 (2.8–60)  32.7 (20–47.5)  34.6 (17.2–55.7) 
rEpC1-GST  16.7 (7–31.3)  29.4 (10.3–56)  33.3 (7.5–70)  18.4 (8.8–32)  26.9 (11.6–47.8) 
*CI, confidence interval; IBCF, antigen was bovine hydatid cyst fluid; rEpC1-GST, antigen was recombinant EpC1 glutathione S-transferase. 
†Frequency of positive abdominal ultrasonographic results. 
‡Frequency of positive chest radiographic results. 
§Ultrasonography, radiography, or both. RESEARCH
similar to previously reported rates from other central high-
land communities in Peru (4.9%–5.7%) (12,14). However, 
a study in Vichaycocha (north highland) showed a rate of 
9.3% by ultrasonography and radiography, and a seropos-
itivity rate of 18.2% (11). These rates are comparable to 
the highest reported prevalences in other countries such as 
China (liver CE from 3.3% to 6.6% [22,23]), Kenya (5.6% 
liver CE [1]), and Argentina before initiation of its control 
program (5.6% in school children [24]).
Unlike some other areas of Peru, Yanahuanca has not 
had a CE control program. This might explain, at least in 
part, why the overall prevalence in our survey was as high 
as 12.5% when ultrasonography, radiography, and IBCF 
results were combined and up to 23.8% when ultrasonogra-
phy, radiography, and rEpC1-GST results were combined. 
Notwithstanding, these ﬁ  gures do not represent the true 
disease prevalence because they might reﬂ  ect the continu-
ous transmission and endemicity of E. granulosus in this 
region. Diagnostic approaches for CE based on imaging 
techniques can be problematic because of variations in size, 
shape, and location of the cysts. In addition, E. granulosus 
distribution, host susceptibility, and strain variation might 
affect disease transmission in different areas of the Peru-
vian Highlands (to our knowledge, no studies have tried to 
characterize E. granulosus strains in Peru).
One of the underlying weaknesses of this study was 
the lack of a true standard (a test with 100% sensitivity and 
100% speciﬁ  city), which would enable evaluation of al-
ternative diagnostic tests and underlying prevalence. Most 
areas of medicine lack a true standard, yet recent statistical 
techniques have been developed that can help evaluate di-
agnostic tests and estimate true prevalence in the absence 
of such a standard. Most of these techniques rely upon a 
Bayesian framework (25–27) and are computationally in-
tensive but more ﬂ  exible than maximum likelihood–based 
approaches because they can incorporate correlation among 
diagnostic tests. Although the Bayesian approach offers 
distinct advantages, potential problems include speciﬁ  ca-
tion of an appropriate prior distribution and a nonidentiﬁ  -
able model. Our study encountered both of these problems 
because reliable prior information is not readily available 
and estimates provided by a Bayesian approach are limited 
by the lack of identiﬁ  able groups.
The poor performances of the IBCF and rEpC1-GST 
testing may be related to false-positive imaging results from 
other space-occupying lesions (e.g., neoplasia, abscesses, 
nonparasitic cysts). Additionally, participants might have 
had low or undetectable levels of circulating antibodies 
from different stages of cyst development or degeneration. 
The production of IgG depends on the number, size, loca-
tion, and condition of the cysts; only 60%–80% of persons 
with conﬁ   rmed CE become seropositive (28). Calciﬁ  ed 
cysts are less seroreactive, thus decreasing seropositivity 
(16,22), as observed in this study. Previous studies using 
the same IBCF testing found that the frequency of seroposi-
tivity was 57% (12) and 53% (14) for liver hydatid cysts 
(ultrasonography), and 13% for lung cysts (11), similar to 
what we found in this study. However, another study, in 
which most of the liver cysts were active, reported a pro-
portion of persons who were positive according to IBCF 
testing to be as high as 73% (11).
Other possible reasons for the limitation of serologic 
testing might be the weak immune response against pul-
monary cysts, cysts at other sites (e.g., brain, eyes, bones, 
ovaries), small or poorly deﬁ  ned cysts, and a thick collagen 
cyst wall that would reduce antigen exposure (29). Howev-
er, increased seropositivity (up to 50%) for detecting large 
hepatic cysts (>20 mm in diameter) has not been reported 
previously and may be due to elevated antigen concen-
trations in these cysts. To our knowledge, the only study 
showing a correlation between cyst size and seropositivity 
was performed in sheep (30).
The different antigen sources would explain the dis-
parity and poor agreement between the 2 serologic tests. 
EpC1 is a recombinant antigen obtained from protosco-
lex larvae from sheep hydatid cysts (17), while the IBCF 
uses bovine hydatid cyst ﬂ  uid (16). The IBCF appears to 
be more responsive than the rEpC1-GST in detecting CE-
image cases. Crude hydatid ﬂ  uid has been recommended 
for mass serologic screening (31) and puriﬁ  ed antigen 5 
(Ag5) and AgB for speciﬁ  c diagnosis. Ag5 and AgB are 
recognized as 2 of the most useful E. granulosus antigens 
for diagnosis (32), although Lorenzo et al. (33) found that 
hydatid cyst ﬂ  uid, AgB, and its subunit AgB8/1 exhibited 
equivalent diagnostic efﬁ  ciencies in a randomized multi-
center study.
Among participants with CE-negative ultrasonography 
images, rEpC1-GST testing detected >3× more seroposi-
tive persons than the IBCF (19% vs. 7.3%, respectively). 
This scenario has been described with other diagnostic test 
such as AgB ELISA, which detected 5.3% CE-seropositive 
persons in a group with CE-negative ultrasonography im-
ages (22). We do not have evidence of cross-reaction with 
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Table 3. Echinococcosis-positive results, by sex, 4 diagnostic 
tests, central Peruvian Highlands* 
Female Male
Test 
No. (%) 
positive Total 
No. (%) 
positive Total 
Ultrasonography†  30 (5.2)  572 15 (4.0)  377
Radiography‡  7 (1.4)  497 2 (0.6)  332
IBCF§ 54 (9.7)  558 29 (7.8)  371
rEpC1-GST¶  113 (20.3)  558 70 (18.8)  371
*By χ
2 analysis, none of the tests showed a significant association between
sexes with positive diagnosis. 
†Abdomen.
‡Chest.
§IBCF, antigen was bovine hydatid cyst fluid. 
¶rEpC1-GST, antigen was recombinant EpC1 glutathione S-transferase. Cystic Echinococcosis, Central Peruvian Highlands
Fasciola for any of the serologic tests used in this study; 
however, Hymenolepis nana, Entamoeba histolytica, Giar-
dia lamblia, and Taenia sp (34) are endemic to the study 
area, which might affect the serodiagnosis. We demonstrat-
ed no cross-reaction with cysticercosis (T. solium) by IBCF 
or rEpC1-GST because the proportion of persons who were 
cysticercosis positive was equal among those who were CE 
seropositive and CE seronegative according to both assays. 
Other possible explanations include past exposure to Echi-
nococcus eggs (aborted infection) that produced only tran-
sient antibodies (35), and undetected cysts.
In our study, the lung-to-liver ratio of 1:5 is higher 
than ratios reported in other epidemiologic studies in Peru 
(11) but within the range of those reported in other Echi-
nococcus-endemic South American countries such as Ar-
gentina, Chile, and Uruguay (1:3–1:13) (11,36). Molecular 
genetic studies of E. granulosus in the Peruvian Highlands 
may clarify some issues about the organ infection prefer-
ences (tropism), tissue survival, infection rates, immune 
responses, and the performance and agreement of immu-
nodiagnostic tests.
Among liver cysts, 54% were CE5 and 20% were CE1; 
other studies have typically displayed an exponential de-
cline in the frequency of liver cyst types from CE1 (most 
frequent) to CE5 (most rare) (37). Because most of these 
persons had not received a diagnosis of hydatid disease or 
antihelminthic treatment, these calciﬁ  ed forms are most 
probably the result of the natural process of degeneration 
driven by individual immune responses (38). A proportion 
of hydatid cysts die after initial establishment; thus, calci-
ﬁ  ed lesions can be observed macroscopically (29). The geo-
graphic variation of cyst type frequencies can also depend 
on the time between infection and evaluation, the immune 
response of a highly exposed population, and E. granulo-
sus genetic variation (15). Calciﬁ  ed cysts may also have 
been misdiagnosed with other lesions from biliary cysts, 
pyogenic abscesses, amebic liver abscesses, or even tumor-
like masses or metastases (39), although these conditions 
are uncommon in Peru. We did not study the speciﬁ  c IgG 
subclasses in relation to cyst types, but their quantiﬁ  cation 
may be important for understanding the natural history of 
hydatid cyst. IgG4 antibody response is associated with de-
velopment, growth, and progression (CE1 to CE3); IgG1, 
IgG2, and IgG3 occur predominantly when cysts became 
inﬁ  ltrated or degenerated (CE4 and CE5) (40).
Our study provides data on CE in the surveyed com-
munities and shows the results of using ultrasonography, 
radiography, and immunodiagnosis for large-scale popu-
lation screening. Determining baseline prevalence with 
ultrasonography enables the evaluation of epidemiologic 
surveillance activities and study of the natural history of 
CE. Ultrasonography is well accepted by the population 
and is relatively less expensive than other imaging tech-
niques. Methods that are inexpensive and relatively easy 
to use, such as immunodiagnosis and ultrasonography, are 
required for large-scale screening of populations in which 
hydatidosis is endemic. However, serologic assays have 
serious limitations under ﬁ  eld conditions, as has been dem-
onstrated in this study. Seroepidemiologic surveys for CE 
require better diagnostic antigens and should be supported 
by imaging methods whenever possible.
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